Date | Price Target | Rating | Analyst |
---|---|---|---|
1/18/2022 | Buy → Neutral | Guggenheim | |
1/5/2022 | $22.00 → $16.00 | Outperform | Oppenheimer |
11/10/2021 | $22.00 → $18.00 | Market Outperform | JMP Securities |
Gainers Sharps Technology (NASDAQ:STSS) stock increased by 87.0% to $0.4 during Monday's after-market session. The company's market cap stands at $6.2 million. MorphoSys (NASDAQ:MOR) stock increased by 25.94% to $23.35. The market value of their outstanding shares is at $3.5 billion. Kintara Therapeutics (NASDAQ:KTRA) shares increased by 12.49% to $0.19. The market value of their outstanding shares is at $10.4 million. Mustang Bio (NASDAQ:MBIO) stock moved upwards by 11.91% to $0.23. The market value of their outstanding shares is at $2.9 million. icad (NASDAQ:ICAD) shares moved upwards by 10.75% to $1.75. The market value of their outstanding shares is at $46.4 million. Renalytix (NAS
icad (NASDAQ:ICAD) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 58.33 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $4.95 million which beat the analyst consensus estimate of $4.44 million by 11.58 percent. This is a 14.31 percent increase over sales of $4.33 million the same period last year.
NASHUA, N.H., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 on September 24 and 25, 2024. CEO, Dana Brown and CFO, Eric Lonnqvist will deliver a company presentation at 11:00 am ET on September 24, and host one-on-one meetings the following day, September 25. To learn more about the iAccess Alpha Buyside Best Ideas Fall Conference 2024, or to register and schedule a one-on-one meeting with iCAD, please vis
NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024. Second Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.2 million, up 7%Total revenues were $5.0 million, up 21%Gross Profit Margin was 84%, up from 81%GAAP Net loss from continuing operations ($1.7) million, improvement from ($2.3 million) "The second quarter of 2024 was highlighted by strong revenue growth of 21%, which demonstrat
NASHUA, N.H., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the second quarter ended June 30, 2024 after market close and host a conference call at 4:30 PM Eastern Time on Tuesday, August 13, 2024. Earnings call details are as follows: Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 227167Webcast: https://www.webcaster4.com/Webcast/Page/2879/50989 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that ena
NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024. Second Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.2 million, up 7%Total revenues were $5.0 million, up 21%Gross Profit Margin was 84%, up from 81%GAAP Net loss from continuing operations ($1.7) million, improvement from ($2.3 million) "The second quarter of 2024 was highlighted by strong revenue growth of 21%, which demonstrat
NASHUA, N.H., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the second quarter ended June 30, 2024 after market close and host a conference call at 4:30 PM Eastern Time on Tuesday, August 13, 2024. Earnings call details are as follows: Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 227167Webcast: https://www.webcaster4.com/Webcast/Page/2879/50989 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that ena
NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.0 million, up 10%Total revenues were $5.0 million, up 14%Gross Profit Margin % was 83%, up from 82%GAAP Net Loss from continuing operations ($1.2) million, improvement from ($3.1) millionOperating cash flow was ($1.2) million, improvement from ($1.5) million "Over the past year, we have demonstrated strong
Guggenheim downgraded icad from Buy to Neutral
Oppenheimer reiterated coverage of icad with a rating of Outperform and set a new price target of $16.00 from $22.00 previously
JMP Securities reiterated coverage of icad with a rating of Market Outperform and set a new price target of $18.00 from $22.00 previously
4 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
4 - ICAD INC (0000749660) (Issuer)
SC 13G/A - ICAD INC (0000749660) (Subject)
SC 13G/A - ICAD INC (0000749660) (Subject)
SC 13G - ICAD INC (0000749660) (Subject)
10-Q/A - ICAD INC (0000749660) (Filer)
8-K - ICAD INC (0000749660) (Filer)
S-8 - ICAD INC (0000749660) (Filer)
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Dr. Hricak to its Board of Directors, effective immediately. Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field. For more than 20 years, she was Chair of the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK) in New York City, a position from which she stepped down in January 2023. She continues to serve on the faculty of MSK; she holds the C
NASHUA, N.H., Jan. 30, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Michael J. Doyle to its Board of Directors, effective immediately. Mr. Doyle is a seasoned technology and healthcare executive with over 35 years of experience. He is currently the CEO of Spire Health, a leading healthcare technology company focused on improving health outcomes for cardiorespiratory patients through continuous virtual patient monitoring. Spire along with Mr. Doyle's recent companies all achieved measu
NASHUA, N.H., April 17, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Eric Lonnqvist as Chief Financial Officer (CFO), effective immediately, as well as Vasu Avadhanula as Chief Product Officer (CPO) and Michelle Strong as Chief Operations Officer (COO), effective May 1. "As we explore new strategic approaches to execute our mission and expand our impact worldwide, experienced and visionary leadership is critical to the success of our organization. Eric, Vasu, and Michelle bring proven expertise to drive growth, increas